A

Amgen

Makes biotech medicines for serious illnesses

Finance Data Senior Manager

Full-TimeUpdated on 10/22/2026
No salary listed
Expert
Bachelor's
Hyderabad, Telangana, India
In Person
Data & AnalyticsData Management

About the job

Requirements
  • A bachelor's degree in Finance, Accounting, Information Systems, Data Management, Business Administration, a STEM discipline, or a related field.
  • At least 8 years of experience in Finance Master Data Management, Data Governance, Finance Operations, or Finance Transformation.
  • Experience leading enterprise-wide data governance, master data, or ERP transformation initiatives.
  • A strong understanding of Finance business processes, controls, and reporting requirements.
Responsibilities
  • Own governance and lifecycle management of Finance subdomains and data objects, including GL Accounts, Company Code extensions, Profit Centers and hierarchies, Cost Centers and hierarchies, WBS Elements, Expense Projects, Sales Organization Hierarchies, Country Chart of Accounts, Financial Statement Versions, Account Group Hierarchies, and related reference data.
  • Serve as Finance Sub-Domain Data Lead, translating enterprise data governance policies into finance-specific standards, SOPs, training materials, business rules, and governance playbooks.
  • Drive process-to-data mapping across Record-to-Report, FP&A, Tax, General Accounting, and other Finance processes to establish ownership, accountability, critical data elements, and governance controls.
  • Lead Finance master data governance forums and partner with Domain Data Leads, Data Stewards, business process owners, and technology teams to align governance priorities and business outcomes.
  • Establish and monitor data quality metrics, KPIs, controls, and remediation plans to improve the accuracy, completeness, consistency, and timeliness of Finance master data.
  • Own Finance master data workflows and approval processes, ensuring appropriate controls, segregation of duties, compliance requirements, and audit readiness.
  • Partner with business stakeholders to evaluate impacts of organizational, financial, regulatory, and system changes on Finance master data structures and governance processes.
  • Drive metadata management, business definitions, lineage documentation, and critical data element governance to support trusted reporting and analytics.
  • Identify governance adoption challenges and continuously improve standards, templates, guidance, controls, and reusable governance assets through stakeholder feedback.
  • Support enterprise data strategy objectives, AI readiness initiatives, and data product enablement by ensuring Finance data is trusted, governed, and fit for purpose.
  • Escalate material data risks, governance exceptions, quality issues, and compliance concerns to Domain Data Leads and governance councils as appropriate.
  • Collaborate with internal and external audit teams and maintain governance evidence required to support regulatory, financial, and compliance reviews.
  • Lead and mentor Finance Data Stewards while fostering a culture of data accountability, stewardship, and continuous improvement.
  • Enable adoption of enterprise governance standards across Finance subdomains.
  • Drive awareness of data ownership, stewardship, and accountability across Finance organizations.
  • Embed governance controls into operational workflows and system processes.
  • Resolve data definition, hierarchy, ownership, and metric alignment issues.
  • Support governance maturity assessments and continuous improvement initiatives.
  • Represent Finance subdomain data interests within Enterprise Data Enablement and Functional Data Enablement Councils.
  • Ensure compliance-by-design principles are embedded across Finance data processes and transformation programs.
Desired Qualifications
  • Deep expertise in Finance master data domains, including GL Accounts, Cost Centers, Profit Centers, WBS, Project Systems, Hierarchies, and Chart of Accounts.
  • Experience supporting SAP ECC and SAP S/4HANA Finance implementations and migrations.
  • Knowledge of SAP MDG, data quality platforms, metadata management, and governance tools.
  • Experience establishing governance operating models, stewardship programs, and data quality frameworks.
  • Understanding of data lineage, metadata, critical data elements, and audit requirements.
  • Experience supporting analytics, reporting, AI, and data product initiatives.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.